May 13, 2019 08:47 AM EDTUpdated 10:59 AM

‘Too big to care’: Sweeping lawsuit accuses Teva of colluding with other generic makers to keep prices high

Amber Tong

Teva has been accused of being a ringleader in a massive price-fixing conspiracy alongside 19 other generic drugmakers in the US, causing price spikes of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Too big to care’: Sweeping lawsuit accuses Teva of colluding with other generic makers to keep prices high

Amber Tong

Sign up to read this article for free.

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

‘Too big to care’: Sweep­ing law­suit ac­cus­es Te­va of col­lud­ing with oth­er gener­ic mak­ers to keep prices high

Amber Tong

Sign up to read this article for free.

more like this

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

‘Too big to care’: Sweeping lawsuit accuses Teva of colluding with other generic makers to keep prices high

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Updated: Roche buys out CAR-T partner Poseida for $1B upfront